Clarity Pharmaceuticals announced that a complete response—based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessment—was observed in the first patient with metastatic castration-resistant prostate cancer (mCRPC) to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq. The patient is being treated in Clarity’s SECuRE trial, a phase 1/2a theranostic trial for identification and treatment of prostate-specific membrane antigen (PSMA)-expressing mCRPC using targeted copper theranostics. In the trial, 64Cu-SAR-bisPSMA is used to visualize PSMA-expressing lesions and select candidates for subsequent 67Cu-SAR-bisPSMA ...
RLT
Advertisement
Latest News
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
